- Overview
- Bayer Group
- Stock
- Bonds
- Reports
- Annual Stockholders’ Meeting 2019
- Events
- Inside Information
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
Investor Conference Call on Xarelto COMPASS Data at ESC Congress 2017
Monday, August 28, 2017
Start approx. 1:30 p.m. CEST (11:30 a.m. UTC)
Full data from the Phase III COMPASS Study with Xarelto (Rivaroxaban) have been featured in Hot Line presentations at ESC Congress 2017 on August 27, 2017 in Barcelona, Spain. On this occasion we hosted a conference call for investors and analysts on August 28, 2017.
Investor News on Xarelto COMPASS Data

Dr. Jörg Möller
Head of Global Development at Pharmaceuticals

Dr. Frank Misselwitz
Head of the Therapeutic Area Thrombosis and Hematology
with
Dr. Jörg Möller, Head of Global Development at Pharmaceuticals
Dr. Frank Misselwitz, Head of the Therapeutic Area Thrombosis and Hematology
Oliver Maier, Head of Bayer Investor Relations
Audio recording of the investor conference call
(MP3 format)
You can also play the audio recording on your mobile device.
Presentation Charts | Download PDF collect (947 KB) |
Transcript | Download PDF collect (64 KB) |